Drugs and devices Archives

Drugs and devices, Immunology and allergy, Respiratory and sleep

Videos

Modulite® inhaler technology: Practical device features for asthma and COPD management

In this Quick Case, Consultant Pharmacist A/Prof Debbie Rigby discusses the role of Modulite® technology in asthma and COPD inhalers, highlighting device characteristics, inhaler selection considerations, and the potential relationship of extrafine (<2 µm MMAD) particle delivery on lung deposition (4 mins).

Expert/s: A/Prof Debbie Rigby

Drugs and devices

Clinical Articles

Adverse event reporting is worryingly low — does the system need an overhaul?

The clunky process is a major issue, especially for unexpected AEs...

Expert/s: Lynnette Hoffman, Ruby Prosser Scully

Drugs and devices, Mental health

Podcasts

Beyond the script: A whole-person workup for mild to moderate depression in general practice

Explore whether medication is being prescribed too readily for mild-to-moderate mood symptoms, and how a structured, whole-person assessment can guide more effective care during the first few GP consultations.

Expert/s: Prof Jerome Sarris

Drugs and devices, Respiratory and sleep

Videos

Triple therapy in COPD: Re-evaluating inhaled corticosteroids, exacerbations and pneumonia risk

In this Product Explainer, General Practitioner Prof David Price explains how single-inhaler triple therapy can reduce COPD exacerbations and the different ICS molecules pneumonia risk profiles, with evidence from both randomised trials and real-world studies (5 mins).

Expert/s: Prof David Price

Drugs and devices

Clinical Articles

How genes can impact medication response

When can pharmacogenomic testing make a meaningful difference and what are the pitfalls to be aware of?

Expert/s: Sophia Auld

Drugs and devices

Clinical Articles

IV iron formulation and fracture risk: new study

Recent research has linked FCM to increased fracture risk, here's what GPs need to know...

Expert/s: Clinical A/Prof Pradeep Jayasuriya

Drugs and devices

Clinical Articles

Peptide use in Australia – What GPs need to know

Key takeaways from the recent FDA decision and new warnings from the Medical Board...

Expert/s: Prof Gary Wittert

Drugs and devices, Politics

Clinical Articles

How drug companies are playing hardball with Australia’s PBS

What's really going on in the background and how could it impact access to subsidised medicines?

Expert/s: Healthed

Drugs and devices

Podcasts

Medicinal cannabis: Practical prescribing, safety and pathways

Emergency Physician and Medicinal Cannabis Specialist Dr Crosby Rechtin joins host Dr Rebecca Overton to demystify prescribing medicinal cannabis in Australian general practice.

Expert/s: Dr Crosby Rechtin

Drugs and devices

Clinical Articles

Rules for administering MDMA and psilocybin have been relaxed

Could the TGA changes lead psychedelic therapies down the path of commercialisation?

Expert/s: Healthed

Drugs and devices, Respiratory and sleep

Videos

Real-world outcomes in adult asthma with triple therapy

In this Product Explainer, Respiratory and Sleep Physician, Dr Nick Wilsmore discusses the role of triple therapy in adult asthma, highlighting the importance of bronchoprotection, along with real-world evidence demonstrating outcomes in patients switched to triple therapy (5 mins).

Expert/s: Dr Nick Wilsmore

Drugs and devices, Geriatric medicine

Clinical Articles

Older adults increasingly dying from drug overdoses

Over 50s are most likely to overdose, experts explain what's going on...

Expert/s: Healthed

Drugs and devices

Modulite® inhaler technology: Practical device features for asthma and COPD management

Adverse event reporting is worryingly low — does the system need an overhaul?

The clunky process is a major issue, especially for unexpected AEs...

Beyond the script: A whole-person workup for mild to moderate depression in general practice

Explore whether medication is being prescribed too readily for mild-to-moderate mood symptoms, and how a structured, whole-person assessment can guide more effective care during the first few GP consultations.

Triple therapy in COPD: Re-evaluating inhaled corticosteroids, exacerbations and pneumonia risk

In this Product Explainer, General Practitioner Prof David Price explains how single-inhaler triple therapy can reduce COPD exacerbations and the different ICS molecules pneumonia risk profiles, with evidence from both randomised trials and real-world studies (5 mins).

How genes can impact medication response

When can pharmacogenomic testing make a meaningful difference and what are the pitfalls to be aware of?

IV iron formulation and fracture risk: new study

Recent research has linked FCM to increased fracture risk, here's what GPs need to know...

Peptide use in Australia – What GPs need to know

Key takeaways from the recent FDA decision and new warnings from the Medical Board...

How drug companies are playing hardball with Australia’s PBS

What's really going on in the background and how could it impact access to subsidised medicines?

Medicinal cannabis: Practical prescribing, safety and pathways

Emergency Physician and Medicinal Cannabis Specialist Dr Crosby Rechtin joins host Dr Rebecca Overton to demystify prescribing medicinal cannabis in Australian general practice.

Rules for administering MDMA and psilocybin have been relaxed

Could the TGA changes lead psychedelic therapies down the path of commercialisation?

Real-world outcomes in adult asthma with triple therapy

In this Product Explainer, Respiratory and Sleep Physician, Dr Nick Wilsmore discusses the role of triple therapy in adult asthma, highlighting the importance of bronchoprotection, along with real-world evidence demonstrating outcomes in patients switched to triple therapy (5 mins).

Older adults increasingly dying from drug overdoses

Over 50s are most likely to overdose, experts explain what's going on...

Get the app

Site

Company

Connect

Legal

Discover

Healthed

Upcoming Healthed Webcast

New Brain Health Guidelines – What GPs Can Do

Tuesday 4th August, 7pm - 9pm AEST

Speaker

Scientia Prof Kaarin Anstey

Psychologist; Director, UNSW Ageing Futures Institute; ARC Laureate Fellow; Senior Principal Research Scientist, NeuRA

Scientia Prof Kaarin Anstey translates the WHO's updated 2026 dementia risk-reduction guidelines changes into concrete actions for opportunistic risk assessment and targeted advice in everyday general practice.

Drugs and devices

The clunky process is a major issue, especially for unexpected AEs...

Explore whether medication is being prescribed too readily for mild-to-moderate mood symptoms, and how a structured, whole-person assessment can guide more effective care during the first few GP consultations.

In this Product Explainer, General Practitioner Prof David Price explains how single-inhaler triple therapy can reduce COPD exacerbations and the different ICS molecules pneumonia risk profiles, with evidence from both randomised trials and real-world studies (5 mins).

When can pharmacogenomic testing make a meaningful difference and what are the pitfalls to be aware of?

Recent research has linked FCM to increased fracture risk, here's what GPs need to know...

Key takeaways from the recent FDA decision and new warnings from the Medical Board...

What's really going on in the background and how could it impact access to subsidised medicines?

Emergency Physician and Medicinal Cannabis Specialist Dr Crosby Rechtin joins host Dr Rebecca Overton to demystify prescribing medicinal cannabis in Australian general practice.

Could the TGA changes lead psychedelic therapies down the path of commercialisation?

In this Product Explainer, Respiratory and Sleep Physician, Dr Nick Wilsmore discusses the role of triple therapy in adult asthma, highlighting the importance of bronchoprotection, along with real-world evidence demonstrating outcomes in patients switched to triple therapy (5 mins).

Over 50s are most likely to overdose, experts explain what's going on...

Save time on registrations, track CPD, listen to full podcasts... sign in to your Healthed account now

Don't have an existing account? Sign up today

Sign up for a free Healthed account

Extra Details

PASSWORD RESET

Discover

Healthed

Upcoming Healthed Webcast

New Brain Health Guidelines – What GPs Can Do

Tuesday 4th August, 7pm - 9pm AEST

Speaker

Scientia Prof Kaarin Anstey

Psychologist; Director, UNSW Ageing Futures Institute; ARC Laureate Fellow; Senior Principal Research Scientist, NeuRA

Scientia Prof Kaarin Anstey translates the WHO's updated 2026 dementia risk-reduction guidelines changes into concrete actions for opportunistic risk assessment and targeted advice in everyday general practice.